Models:
Joseph Gordon
joseph-gordon/
CTEligible
0
Downloads: 1
[cbecd8]: / nci_data / dataset1-trials / WBC_CTEP Trials_072018.tsv

Download this file

# nci_id nct_id official_title inclusion_indicaInclusionor description Text Boolean
1 NCI-2009-00336 NCT00392327 Efficacy of Carboplatin Administered Concomitantly with Radiation and Isotretinoin as a Pro-apoptotic Agent in Other than Average Risk Medulloblastoma/PNET Patients N/A
2 NCI-2009-00470 NCT00632853 Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin or Carboplatin and Etoposide N/A
3 NCI-2009-00595 NCT00719303 Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival? N/A
4 NCI-2009-00603 NCT00492778 A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus N/A
5 NCI-2009-00817 NCT00001337 Dose-Adjusted EPOCH Chemotherapy and Rituximab (Cd20+) in Adults and Children with Previously Untreated Aggressive Non-Hodgkin's Lymphoma N/A
6 NCI-2009-01057 NCT00576654 A Phase I Dose-Escalation Study of Oral ABT-888 (NSC #737664) plus Intravenous Irinotecan (CPT-11, NSC#616348) Administered in Patients with Advanced Solid Tumors N/A
7 NCI-2011-00312 NCT01012817 A Phase 1/2 Trial of ABT-888, an Inhibitor of Poly(ADP-ribose) Polymerase (PARP), and Topotecan (TPT) in Patients with Solid Tumors (Phase 1) and Relapsed Ovarian Cancer or Primary Peritoneal Cancer (Phase 2) after Prior Platinum Containing First-Line Chemotherapy N/A
8 NCI-2011-00878 NCT00956007 A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer N/A
9 NCI-2011-01915 NCT00887146 N0577 (CODEL): Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma N/A
10 NCI-2011-01972 NCT00983697 A Multicenter Trial of FDG-PET/CT Staging of Head and Neck Cancer and Its Impact on the N0 Neck Surgical Treatment in Head and Neck Cancer Patients N/A
11 NCI-2011-01973 NCT00980954 Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma following Radical Hysterectomy N/A
12 NCI-2011-01974 NCT00981656 A Phase II Protocol for Patients with Stage T1 Bladder Cancer to Evaluate Selective Bladder Preserving Treatment by Radiation Therapy Concurrent with Radiosensitizing Chemotherapy following a Thorough Transurethral Surgical Re-staging Inclusion White blood cell count (WBC) >= 4,000/ml Leukocyte count greater than or equal to 4000 per mililiter (C51948 >= 4000/mL)
13 NCI-2011-01975 NCT00980460 Treatment of Children with All Stages of Hepatoblastoma with Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment N/A
14 NCI-2011-01987 NCT01013649 A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma N/A
15 NCI-2011-01992 NCT02085408 Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years) N/A
16 NCI-2011-02000 NCT01042522 A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary N/A
17 NCI-2011-02029 NCT01096368 Phase III Randomized Trial of Post-radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 Years N/A
18 NCI-2011-02034 NCT01118026 Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL) N/A
19 NCI-2011-02037 NCT01101451 Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy N/A
20 NCI-2011-02073 NCT02589938 A Phase III Prospective Randomized Trial of Acupuncture for Treatment_x000D_ of Radiation-Induced Xerostomia in Patients with Head and Neck Cancer N/A
21 NCI-2011-02500 NCT01366144 An Early Phase 1 Study of ABT-888 in Combination with Carboplatin and Paclitaxel in Patients with Hepatic or Renal Dysfunction and Solid Tumors N/A
22 NCI-2011-02515 NCT01051635 A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults with Relapsed Solid Tumors and Lymphomas N/A
23 NCI-2011-02539 NCT01226940 A Phase I Trial of Lenalidomide and Radiotherapy in Children with Diffuse Intrinsic Pontine Gliomas and High-Grade Gliomas N/A
24 NCI-2011-02592 NCT01386385 A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy with Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811) N/A
25 NCI-2011-02594 NCT01381718 A Phase II Placebo-Controlled Trial of Modafinil to Improve_x000D_ Neurocognitive Deficits in Children Treated for a Primary Brain Tumor N/A
26 NCI-2011-02599 NCT01190930 Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy) Inclusion B-ALL patients must have an initial white blood cell count < 50,000/uL initial white blood cell count less than 50,000 per microliter (C8644 = YES) AND (C51948 <= 50000/uL) OR (C8644 = NO)
27 NCI-2011-02611 NCT01231906 A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-Metastatic Ewing Sarcoma N/A
28 NCI-2011-02623 NCT01272037 A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer N/A
29 NCI-2011-02660 NCT01275664 Pilot Study of Standard Therapy for Prevention of Nausea and Emesis Associated with First Line Post-Operative Intraperitoneal Chemotherapy N/A
30 NCI-2011-02673 NCT01359592 A Phase II Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL) N/A
31 NCI-2011-02674 NCT01368588 Androgen Deprivation Therapy and High Dose Radiotherapy with or without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial N/A
32 NCI-2011-03458 NCT01434316 Phase 1 Trial of ABT-888 and SCH727965 in Patients with Advanced Solid Tumors N/A
33 NCI-2011-03797 NCT02883049 A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) including a Stratum Evaluating Dasatinib (NSC#732517) in Patients with Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations Inclusion White Blood Cell Count (WBC) Criteria * Age 1-9.99 years: WBC >= 50 000/uL * Age 10-30.99 years: Any WBC * Age 1-30.99 years: Any WBC with: ** Testicular leukemia ** CNS leukemia (CNS3) ** Steroid pretreatment between age 1 and 9.99 white blood count greater than or equal to 50000 / uL , between age 10 and 31.99 any white blood count, between age 1 and 31.99 any white blood count with testicular leukemia, CNS leukemia, or steroid treatment (C25150>= 1 a AND C25150 < 10 a AND C51948 >= 50000/ uL) OR (C25150 >= 10 a AND C25150 < 31 a ) OR (C25150 >= 1 a AND C25150 < 31 a AND ( C9277 = YES OR C5440 = YES OR C15370 = YES)
34 NCI-2012-00095 NCT01497444 Study of Sorafenib + TH-302: Phase I in Advanced Renal Cell Carcinoma (RCC) and Advanced Hepatocellular Carcinoma (HCC) and Phase II in 1st Line Advanced HCC N/A
35 NCI-2012-00105 NCT01503632 A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL N/A
36 NCI-2012-00112 NCT01503086 Computerized Cognitive Training for Pediatric Brain Tumor Patients: A Pilot Study N/A
37 NCI-2012-00234 NCT01515787 A Phase II/III Trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision N/A
38 NCI-2012-00680 NCT01333046 Administration of Tumor-Associated Antigen (TAA)-Specific Cytotoxic T-Lymphocytes to Patients with Active or Relapsed Hodgkin or Non-Hodgkin Lymphoma N/A
39 NCI-2012-00707 NCT01556243 Impact of Breast Conservation Surgery on Surgical Outcomes and Cosmesis in Patients with Multiple Ipsilateral Breast Cancers (MIBC) N/A
40 NCI-2012-00719 NCT01573442 Randomized Double-Blind Placebo Controlled Study of Testosterone in the Adjuvant Treatment of Postmenopausal Women with Aromatase Inhibitor Induced Arthralgias Inclusion White blood cell (WBC) > 3.0 Leukocyte count greater than or equal to 3000 per microliter (C51948 >= 3000/uL)
41 NCI-2012-00860 NCT01587352 A Phase 2 Study of Vorinostat (NSC 701852) in Metastatic Uveal Melanoma Inclusion Leukocytes >= 3,000/mcL Leukocyte count greater than or equal to 3000 per microliter (C51948 >= 3000/uL)
42 NCI-2012-00864 NCT01585805 A Randomized Phase II Study of Gemcitabine, Cisplatin +/- Veliparib in Patients with Pancreas Adenocarcinoma and a Known BRCA/ PALB2 Mutation (Part I) and a Phase II Single Arm Study of Single-Agent Veliparib in Previously Treated Pancreas Adenocarcinoma (Part II) N/A
43 NCI-2012-01040 NCT01638533 A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients with, Lymphomas, Chronic Lymphocytic Leukemia and Select Solid Tumors and Varying Degrees of Liver Dysfunction N/A
44 NCI-2012-01695 NCT01775475 Randomized, Phase II Trial of CHOP vs. Oral Chemotherapy with Concomitant Antiretroviral Therapy in Patients with HIV-Associated Lymphoma in Sub-Saharan Africa Inclusion White blood cells (WBC) >= 3,000 cells/uL (3.0 x 10^9 L) or Leukocyte count greater than or equal to 3000 per microliter (C51948 >= 3000/uL)
45 NCI-2012-01712 NCT01695941 A Phase I Study of MLN8237 in Combination with Bortezomib and Rituximab in Relapsed and Refractory Mantle Cell and Low Grade Non-Hodgkin Lymphoma Inclusion Leukocytes >= 3,000/mcL Leukocyte count greater than or equal to 3000 per microliter (C51948 >= 3000/uL)
46 NCI-2012-01964 NCT01595061 A Phase II Trial Evaluating Cisplatin (NSC #119875) and Gemcitabine (NSC #613327) Concurrent with Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva (NCT #01595061) N/A
47 NCI-2012-01967 NCT01602666 Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT) N/A
48 NCI-2012-01977 NCT01622868 Phase II Randomized Study of Whole Brain Radiotherapy/Stereotactic Radiosurgery in Combination with Concurrent Lapatinib in Patients with Brain Metastasis from HER2-Positive Breast Cancer: A Collaborative Study of NRG Oncology and KROG N/A
49 NCI-2012-01990 NCT01649089 Evaluation of Physical Function and Quality of Life (QOL) before and after Non-radical Surgical Therapy (Extra Fascial Hysterectomy or Cone Biopsy with Pelvic Lymphadenectomy) for Stage IA1 (LVSI+) and IA2-IB1 (≤ 2CM) Cervical Cancer N/A
50 NCI-2012-01995 NCT01674140 Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer. e^3 Breast Cancer Study-Evaluating Everolimus with Endocrine Therapy. N/A
51 NCI-2012-01998 NCT01668719 A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide with or without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM) N/A
52 NCI-2012-02009 NCT01711541 Carboplatin-Paclitaxel Induction Chemotherapy and ABT-888 (Veliparib) - a Phase 1/Randomized Phase 2 Study in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Inclusion Leukocytes >= 3,000/mm^3 Leukocyte count greater than or equal to 3000 per microliter (C51948 >= 3000/uL)
53 NCI-2012-02011 NCT01711554 A Phase I Study of Lenalidomide and Anti-GD2 Mab Ch14.18 +/- Isotretinoin in Patients with Refractory/Recurrent Neuroblastoma N/A
54 NCI-2012-02020 NCT01781468 A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) to_x000D_ Reduce Cancer-Related Fatigue in Patients with High Grade Glioma N/A
55 NCI-2012-02045 NCT01805076 Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer N/A
56 NCI-2012-02057 NCT01730937 Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma N/A
57 NCI-2012-02067 NCT01349881 A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III- Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES) Inclusion Total white blood cells (WBC) >= 4.0 x 10^3/mcL Leukocyte count greater than or equal to 4000 per microliter (C51948 >= 4000/uL)
58 NCI-2012-02078 NCT01789684 A Cluster Randomized Controlled Trial Comparing Interventions to Enhance Utilization of Genetics_x000D_ Services Among Breast Cancer Patients N/A
59 NCI-2012-02608 NCT01863550 Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) versus Carfilzomib, Lenalidomide, Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE) N/A
60 NCI-2012-02767 NCT01749397 A Phase I Trial of the Combination of the PARP Inhibitor ABT-888 with Intraperitoneal Floxuridine (FUDR) in Epithelial Ovarian, Primary Peritoneal and Fallopian Tube Cancers N/A
61 NCI-2012-02869 NCT01806129 EROS: Engendering Reproductive Health within Oncologic Survivorship N/A
62 NCI-2012-02875 NCT01586403 Transfer of Genetically Engineered Lymphocytes in Melanoma Patients: A Phase 1 Dose Escalation Study N/A
63 NCI-2012-03124 NCT01755195 A Phase 2 Study of Cabozantinib (XL184), a Dual Inhibitor of MET and VEGFR, in Patients with Metastatic Refractory Soft Tissue Sarcoma Inclusion Leukocytes >= 3,000/mcL Leukocyte count greater than or equal to 3000 per microliter (C51948 >= 3000/uL)
64 NCI-2012-03125 NCT01767194 A Phase II Randomized Trial of Irinotecan/Temozolomide with Temsirolimus (NSC# 683864) or Chimeric 14.18 Antibody (Ch14.18) (NSC# 764038) in Children with Refractory, Relapsed or Progressive Neuroblastoma N/A
65 NCI-2012-03173 NCT01089101 A Phase 1 and Phase II and Re-Treatment Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma N/A
66 NCI-2012-03198 NCT01872975 A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy N/A
67 NCI-2013-00046 NCT01771107 A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage II-IV HIV-Associated Hodgkin Lymphoma N/A
68 NCI-2013-00370 NCT01220583 A Randomized Phase II / Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors N/A
69 NCI-2013-00426 NCT01824836 A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS) N/A
70 NCI-2013-00500 NCT01810913 Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin versus Docetaxel versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck N/A
71 NCI-2013-00595 NCT01817075 Impact of Cleansing with Chlorhexidine Gluconate (CHG) on Reducing Central Line Associated Bloodstream Infection (CLABSI) and Acquisition of Multi-drug Resistant Organisms (MDRO) in Children with Cancer or Those Receiving Allogeneic Hematopoietic Cell Transplantation (HCT) N/A
72 NCI-2013-00716 NCT00978250 Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine with Tetrahydrouridine (FdCyd + THU) N/A
73 NCI-2013-00737 NCT01822496 A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC) N/A
74 NCI-2013-00739 NCT01822509 A Phase I/Ib Study of Ipilimumab or Nivolumab in Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation N/A
75 NCI-2013-00740 NCT01822522 Phase I Trial of Cabozantinib (XL184) for Advanced Solid Tumors in Persons with HIV Infection Inclusion Leukocytes >= 3,000/mcL Leukocyte count greater than or equal to 3000 per microliter (C51948 >= 3000/uL)
76 NCI-2013-00805 NCT01244737 A Phase II Study of [18F] FLT for PET Imaging of Brain Tumors in Children N/A
77 NCI-2013-00826 NCT01841723 A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) for Treatment of Relapsed Hairy Cell Leukemia N/A
78 NCI-2013-00858 NCT01849146 Phase I Study of AZD1775 (MK-1775) with Radiation and Temozolomide in Patients with Newly Diagnosed Glioblastoma and Evaluation of Intratumoral Drug Distribution in Patients with Recurrent Glioblastoma N/A
79 NCI-2013-00875 NCT01901094 A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease after Neoadjuvant Chemotherapy N/A
80 NCI-2013-00877 NCT01851369 A Phase I/II Trial of TRC102 (Methoxyamine HCl) in Combination with Temozolomide in Patients with Relapsed Solid Tumors and Lymphomas N/A
81 NCI-2013-00890 NCT01935934 A Phase 2 Study of XL184 (Cabozantinib) in Recurrent or Metastatic Endometrial Cancer N/A
82 NCI-2013-00998 NCT01881867 A Phase 2 Study of Recombinant Glycosylated Human Interleukin-7 (CYT107) after Completion of Standard FDA Approved Therapy with Sipuleucel-T (Provenge®) for Patients with Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer (mCRPC) N/A
83 NCI-2013-01132 NCT01534598 Phase I Trial of Oral 5-Fluoro-2'-Deoxycytidine with Oral Tetrahydrouridine in Patients with Advanced Solid Tumors N/A
84 NCI-2013-01272 NCT01897012 A Phase 1 Trial of MLN8237 plus Romidepsin for Relapsed/Refractory Aggressive B-Cell and T-Cell Lymphomas N/A
85 NCI-2013-01275 NCT01896999 A Phase I Study with an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab, and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma N/A
86 NCI-2013-01320 NCT01902173 Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination with Dabrafenib and Trametinib in Patients with BRAF Mutant Cancer N/A
87 NCI-2013-01340 NCT01953588 ALTernate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer NeoAdjuvant TrEatment (ALTERNATE) in Postmenopausal Women: A Phase III Study N/A
88 NCI-2013-01357 NCT01912625 A Phase 1 Study of Trametinib in Combination with Chemoradiation for KRAS Mutant Non-small Cell Lung Cancer N/A
89 NCI-2013-01368 NCT01925131 A Phase I Study of Inotuzumab Ozogamicin (NSC-772518) in Combination with CVP (Cyclophosphamide, Vincristine, Prednisone) for Patients with Relapsed/Refractory CD22-Positive Acute Leukemia (including B-ALL, Mixed Phenotypic Leukemia and Burkitt's Leukemia) N/A
90 NCI-2013-01452 NCT00942877 Phase II Study of Cediranib (AZD2171) in Patients with Alveolar Soft Part Sarcoma N/A
91 NCI-2013-01474 NCT01273155 Phase I Pharmacokinetic Study of Belinostat for Solid Tumors and Lymphomas in Patients with Varying Degrees of Hepatic Dysfunction Inclusion Leukocytes >= 3,000/mcL Leukocyte count greater than or equal to 3000 per microliter (C51948 >= 3000/uL)
92 NCI-2013-01475 NCT01273168 Phase I Trial of Z-Endoxifen in Adults with Refractory Hormone Receptor-Positive Breast Cancer, Desmoid Tumors, Gynecologic Tumors, or Other Hormone Receptor-Positive Solid Tumors N/A
93 NCI-2013-01491 NCT01362803 A Phase I/II Study of the Mitogen Activated Protein Kinase Kinase (MEK) 1 Inhibitor Selumetinib (AZD6244; HYD Sulfate) in Children with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN) N/A
94 NCI-2013-01496 NCT01391962 A Phase II Trial in Which Patients with Metastatic Alveolar Soft Part Sarcoma Are Randomized to Either Sunitinib or Cediranib Monotherapy, with Cross-Over at Disease Progression Inclusion Leukocytes >= 3,000/mcL Leukocyte count greater than or equal to 3000 per microliter (C51948 >= 3000/uL)
95 NCI-2013-01520 NCT01572493 A Phase I Study of a Continuous Intravenous Infusion of Recombinant Human IL-15 (rhIL-15) in Adults with Metastatic Cancers N/A
96 NCI-2013-01568 NCT01748825 A Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Inhibitor, in Patients with Advanced Refractory Solid Tumors Inclusion Leukocytes >= 3,000/mcL Leukocyte count greater than or equal to 3000 per microliter (C51948 >= 3000/uL)
97 NCI-2013-01588 NCT01827384 Molecular Profiling-Based Assignment of Cancer Therapy for Patients with Advanced Solid Tumors N/A
98 NCI-2013-01602 NCT01922076 A Phase 1 Study of AZD1775 (MK-1775, IND# 116495) Concurrent with Local Radiation Therapy for the Treatment of Newly Diagnosed Children with Diffuse Intrinsic Pontine Gliomas N/A
99 NCI-2013-01639 NCT01964300 Phase II Study of Peginterferon Alfa-2b (SYLATRON) for Pediatric Patients with Unresectable or Recurrent Craniopharyngioma N/A
100 NCI-2013-01702 NCT02004275 A Phase I/II Study of Pomalidomide, Dexamethasone, and Ixazomib vs.Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Refractory to Lenalidomide and Proteasome Inhibitor-Based Therapy N/A